In short
Clinical trials are studying Ly3454738 in adults with moderate-to-severe atopic dermatitis, also called eczema. These trials are looking at whether Ly3454738 is effective and how it compares with placebo in people who have not used biologic or small-molecule treatments before.
Key points
- Clinical trials of Ly3454738 are studying adults with moderate-to-severe atopic dermatitis, also known as eczema. The main trial is a Phase 2 study and has been completed. It compares Ly3454738 with placebo in people who were biologic-and-small-molecule naïve. The main outcome being measured is EASI-75, which shows whether eczema improves by at least 75%. A total of 262 participants were enrolled in the study.
Trial overview
The available trial studied Ly3454738 in adults with moderate-to-severe atopic dermatitis, which is a long-term skin condition also called eczema.
This was an interventional study, which means the researchers gave a study treatment and measured the results.
The trial was in Phase 2, a stage that looks for early signs that a treatment may work and continues to monitor safety.
Who could join the study
The study was for adult participants with moderate-to-severe atopic dermatitis.
It focused on people who were biologic-and-small-molecule naïve, meaning they had not used those treatment types before.
This helps researchers understand how Ly3454738 performs in a group that has not been treated with these newer medicine types before.
What was studied
The trial compared Ly3454738 with placebo, which is a look-alike treatment that does not contain the active study drug.
The brief study summary says the main goal was to compare the efficacy, or how well the treatment works, of Ly3454738 versus placebo in this patient group.
The trial included treatment given by subcutaneous injection, which means a shot under the skin.
Trial endpoints and results being measured
The main endpoint was the percentage of participants who achieved EASI-75.
EASI stands for Eczema Area and Severity Index, a score used to measure how severe eczema is.
EASI-75 means the score improved by at least 75%, which shows a large improvement in eczema signs and symptoms.
Trial design and treatment groups
The trial was designed as a comparison between Ly3454738 and placebo.
The source data also lists topical treatments and sodium chloride solution in the intervention record, but the clearest study objective provided is the comparison of Ly3454738 versus placebo in moderate-to-severe atopic dermatitis.
Because the source only gives a brief summary, the main patient-relevant detail is that the study tested whether Ly3454738 could improve eczema outcomes better than placebo in adults who had not used biologic or small-molecule therapies before.
Study status and size
The trial is marked as completed.
A total of 262 participants were enrolled.
This makes it a moderate-sized Phase 2 study focused on eczema treatment research.